Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Dmitriy Zamarin; Sven Walderich; Aliya Holland; Qin Zhou; Alexia E Iasonos; Jean M Torrisi; Taha Merghoub; Lewis F Chesebrough; Autumn S Mcdonnell; Jacqueline M Gallagher; Yanyun Li; Travis J Hollmann; Rachel N Grisham; Courtney L Erskine; Mathew S Block; Keith L Knutson; Roisin E O’Cearbhaill; Carol Aghajanian; Jason A Konner

doi:10.1136/jitc-2020-000829

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

XML

Clinical trials monitor

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password